BioSpace News Archive

CARsgen Therapeutics Holdings Limited, a leading biotechnology company focused on innovation and development of chimeric antigen receptor T-cell therapeutics, announced the completion of a USD 186 million Series C Equity Financing.

Amicus Therapeutics announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the Credit Suisse 29th Annual Virtual Healthcare Conference on Monday, November 9, 2020 at 8:00 a.m. ET.

TG Therapeutics, Inc., announced that four abstracts have been accepted for presentation at the upcoming 62nd American Society of Hematology annual meeting and exposition, to be held virtually December 5 – 8, 2020.

Freeline Therapeutics Holdings plc, a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, announced that Mark Baldry, MBA, has been appointed as the Company’s new Chief Commercial Officer

Bio-Techne Corporation announced that Jim Hippel, Chief Financial Officer, will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on Wednesday, November 11, 2020 at 4:15 p.m. EST.

KISQALI® is the first CDK4/6 inhibitor to show statistically significant improvement in overall survival (key secondary endpoint) in advanced breast cancer in pre- and perimenopausal women.

Zimmer Biomet Holdings, Inc., a global leader in musculoskeletal care, announced that President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay will be presenting at the Stifel Virtual Healthcare Conference on Tuesday, November 17, at 11:20 a.m. Eastern Time.

Evogene Ltd., a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces that it will release its financial results for the third quarter of 2020 on Wednesday, November 18, 2020.

Akumin Inc. will host a conference call at 8:30 a.m. Eastern Time, November 12, 2020, to discuss its third quarter 2020 financial results.

Diagnostic gene expression profile test for suspicious pigmented lesions now commercially available in the U.S.